Literature DB >> 19208834

Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.

H-C Jennifer Shen1, Mei He, Anathea Powell, Asha Adem, Dominique Lorang, Charles Heller, Amelia C Grover, Kris Ylaya, Stephen M Hewitt, Stephen J Marx, Allen M Spiegel, Steven K Libutti.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal syndrome caused by mutations in the MEN1 tumor suppressor gene. Whereas the protein product of MEN1, menin, is ubiquitously expressed, somatic loss of the remaining wild-type MEN1 allele results in tumors primarily in parathyroid, pituitary, and endocrine pancreas. To understand the endocrine specificity of the MEN1 syndrome, we evaluated biallelic loss of Men1 by inactivating Men1 in pancreatic progenitor cells using the Cre-lox system. Men1 deletion in progenitor cells that differentiate into exocrine and endocrine pancreas did not affect normal pancreas morphogenesis and development. However, mice having homozygous inactivation of the Men1 in pancreas developed endocrine tumors with no exocrine tumor manifestation, recapitulating phenotypes seen in the MEN1 patients. In the absence of menin, the endocrine pancreas showed increase in cell proliferation, vascularity, and abnormal vascular structures; such changes were lacking in exocrine pancreas. Further analysis revealed that these endocrine manifestations were associated with up-regulation in vascular endothelial growth factor expression in both human and mouse MEN1 pancreatic endocrine tumors. Together, these data suggest the presence of cell-specific factors for menin and a permissive endocrine environment for MEN1 tumorigenesis in endocrine pancreas. Based on our analysis, we propose that menin's ability to maintain cellular and microenvironment integrity might explain the endocrine- restrictive nature of the MEN1 syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208834      PMCID: PMC3879686          DOI: 10.1158/0008-5472.CAN-08-3662

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Distinct distribution of laminin and its integrin receptors in the pancreas.

Authors:  Fang-Xu Jiang; Gaetano Naselli; Leonard C Harrison
Journal:  J Histochem Cytochem       Date:  2002-12       Impact factor: 2.479

2.  A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.

Authors:  J S Crabtree; P C Scacheri; J M Ward; L Garrett-Beal; M R Emmert-Buck; K A Edgemon; D Lorang; S K Libutti; S C Chandrasekharappa; S J Marx; A M Spiegel; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Authors:  S C Chandrasekharappa; S C Guru; P Manickam; S E Olufemi; F S Collins; M R Emmert-Buck; L V Debelenko; Z Zhuang; I A Lubensky; L A Liotta; J S Crabtree; Y Wang; B A Roe; J Weisemann; M S Boguski; S K Agarwal; M B Kester; Y S Kim; C Heppner; Q Dong; A M Spiegel; A L Burns; S J Marx
Journal:  Science       Date:  1997-04-18       Impact factor: 47.728

4.  Loss of wild-type MEN1 gene expression in multiple endocrine neoplasia type 1-associated parathyroid adenoma.

Authors:  L Ludwig; L Schleithoff; H Kessler; P K Wagner; B O Boehm; W Karges
Journal:  Endocr J       Date:  1999-08       Impact factor: 2.349

5.  Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1.

Authors:  C A Stratakis; D H Schussheim; S M Freedman; M F Keil; S D Pack; S K Agarwal; M C Skarulis; R J Weil; I A Lubensky; Z Zhuang; E H Oldfield; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.

Authors:  D S Franklin; V L Godfrey; D A O'Brien; C Deng; Y Xiong
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

7.  Clinical studies of multiple endocrine neoplasia type 1 (MEN1)

Authors:  D Trump; B Farren; C Wooding; J T Pang; G M Besser; K D Buchanan; C R Edwards; D A Heath; C E Jackson; S Jansen; K Lips; J P Monson; D O'Halloran; J Sampson; S M Shalet; M H Wheeler; A Zink; R V Thakker
Journal:  QJM       Date:  1996-09

8.  Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.

Authors:  Joseph A Blansfield; Diana Caragacianu; H Richard Alexander; Michael A Tangrea; Shane Y Morita; Dominique Lorang; Peter Schafer; George Muller; David Stirling; Richard E Royal; Steven K Libutti
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

9.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.

Authors:  Masahiro Inoue; Jeffrey H Hager; Napoleone Ferrara; Hans-Peter Gerber; Douglas Hanahan
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors.

Authors:  Guoqiang Gu; Jolanta Dubauskaite; Douglas A Melton
Journal:  Development       Date:  2002-05       Impact factor: 6.868

View more
  35 in total

1.  In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model.

Authors:  Min-Hui Cui; Craig A Branch; Sean M Cahill; Thomas J Quinn; Asha Adem; Steven K Libutti; Ziqiang Yuan
Journal:  Magn Reson Med       Date:  2014-11-13       Impact factor: 4.668

Review 2.  The Rhox genes.

Authors:  James A MacLean; Miles F Wilkinson
Journal:  Reproduction       Date:  2010-04-29       Impact factor: 3.906

3.  Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours.

Authors:  Steven K Libutti
Journal:  Nat Rev Endocrinol       Date:  2013-06-04       Impact factor: 43.330

4.  Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.

Authors:  Allen M Spiegel; Steven K Libutti
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

5.  The embryonic transcription factor Hlxb9 is a menin interacting partner that controls pancreatic β-cell proliferation and the expression of insulin regulators.

Authors:  Kerong Shi; Vaishali I Parekh; Swarnava Roy; Shruti S Desai; Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2013-02-18       Impact factor: 5.678

6.  Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies.

Authors:  Sunita K Agarwal
Journal:  Int J Endocr Oncol       Date:  2014

Review 7.  Insulinoma: pathophysiology, localization and management.

Authors:  Joyce J Shin; Phillip Gorden; Steven K Libutti
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

8.  Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.

Authors:  S T Glenn; C A Jones; S Sexton; C M LeVea; S M Caraker; G Hajduczok; K W Gross
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

9.  GSK-3β protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation.

Authors:  Shruti S Desai; Sita D Modali; Vaishali I Parekh; Electron Kebebew; Sunita K Agarwal
Journal:  J Biol Chem       Date:  2014-01-14       Impact factor: 5.157

10.  Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress.

Authors:  Amanda R Wasylishen; Chang Sun; Gilda P Chau; Yuan Qi; Xiaoping Su; Michael P Kim; Jeannelyn S Estrella; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.